September 29, 1999
Dow Jones Newswires
BOTHELL, Wash. -- Icos Corp.'s (ICOS) LeukArrest was found safe and well tolerated in a Phase II clinical trial of 45 patients with acute exacerbations of multiple sclerosis, but demonstrated no clinical benefit as determined by changes in the Scripps Scale, a neurological instrument.
In a press release Wednesday, the pharmaceutical development company said the study was designed to evaluate the recovery of neurologic function following exacerbation of a patient's disease.
The company said it will complete a one-year follow up to the study at the end of 1999, but has no plans to study LeukArrest as a chronic treatment for multiple sclerosis at this time.
As a secondary endpoint, the study used MRI technology to assess brain
lesion activity. The results of the trial showed a statistically significant
reduction in the formation of new lesions, suggesting that LeukArrest may
have an effect on the natural history of multiple sclerosis.